2011 News – Press Release:
FOR IMMEDIATE RELEASE
“Contagion” Scenario: Nexera Medical On Leading Edge Of Airborne Microbe Protection With Its Next Generation Surgical Respirator Mask
FORT LAUDERDALE, Florida (September 14, 2011) - Last Friday, September 9th, the movie “Contagion” hit theaters with its story built around an airborne virus that quickly becomes a global pandemic and decimates mankind. While the level of outbreak in the movie is certainly a worst-case scenario, recent outbreaks of the swine and bird flu have shown that airborne viruses are a real threat.
Currently, the medical community is working to identify, understand and stop existing and emerging airborne pathogenic microbes, however, one of the best ways to protect oneself from airborne microbe threats is to prevent the microbes from entering one’s respiratory system in the first place.
Aside from frequent hand washing, staying away from crowds and avoiding people who are sick, wearing a respirator facemask is one of the most affordable and easiest ways to limit the spread of harmful airborne microbes. Wearing respirators is part of the protocol designed by the WHO and CDC to protect people against harmful airborne diseases, and respirators are an integral part of Personal Protective Equipment (“PPE”) as described by medical professionals.
On September 8th, Nexera Medical, Inc. (“Nexera”) announced plans to submit to the U.S. Food and Drug Administration (FDA) amended antimicrobial claims for its current 510(k) clearance for the SpectraShield™ 9500 Surgical N95 Respirator with embedded antimicrobial technology. The expanded antimicrobial claims will be supported by test data on the inactivation performance of certain strains of viruses recognized by the FDA to cause various types of influenzas and colds considered public health issues, including the H1N1 (Swine Flu) Virus, H5N1 (Bird Flu) Virus, Rhino Virus (common cold), and SARS (Severe Acute Respiratory Syndrome).
These tests are very similar to those tests that have already been conducted by Nexera in the European Union. There, the SpectraShield™ Respirator Mask demonstrated its ability to kill these strains of viruses and was certified as an antimicrobial FFP3 respirator mask and has been issued a CE Mark by INSPEC, the applicable jurisdictional agency to certify Class II Medical Devices in the European Union. Additionally, Nexera has pending approval of two additional SpectraShield™ respirator masks as Reusable FFP2 and Reusable FFP3 antimicrobial respirators masks, the first and only masks of their kind in the world. These masks are planned to be commercially available by the end of October in the European Union and other countries that accept or recognize the CE Mark.
Nexera’s president, Paul Sallarulo, stated, “We are pleased to continue take the necessary steps to provide people with the best antimicrobial technology and best respiratory protection available today.” He added, “People have very little protection in the event of a healthcare crisis involving airborne pathogens, and our SpectraShield™ Respirator can provide a person with the highest degree of protection.”
The SpectraShield™ Respirator is designed to capture harmful germs and kill them when they are on the surface of the mask. The respirator also traps and kills any additional germs in the middle filtration layers to prevent them from entering the body and causing an infection. The SpectraShield™ Respirator utilizes a revolutionary antimicrobial technology called Fosshield®, made in the USA by Foss Manufacturing. This antimicrobial technology is currently in use in many industries from hospitality, to healthcare, to apparel.
The SpectraShield™ Respirator is available in adult sizes. This revolutionary next generation respirator is designed to give the general public, health officials, first responders, and care givers the best available protection against infectious diseases.
Nexera plans to roll out a portfolio of other infectious disease preventing textile-based healthcare products made from Fosshield® technology, including other types of surgical and dental masks, mattress pads and covers, warming blankets, hospital uniforms, lab coats, wound care products, and hospital divider curtains to name a few. All of these solutions are designed to assist hospitals in controlling or reducing “hospital acquired infections.” This revolutionary Fosshield® fiber technology is ideally suited for infectious disease prevention, thereby assists in reducing the spread of infectious diseases in any environment.
Nexera Medical Inc. is headquartered in Fort Lauderdale, Florida. The company is engaged in the development, manufacturing, and distribution of antimicrobial respirator and surgical masks, as well as other planned antimicrobial textile based medical products such as medical slings, surgical site aprons and hospital linen products worldwide. All of Nexera’s products are designed to provide maximum protection against microorganisms such as bacteria, virus and fungus using Fosshield® patented technology. Nexera partners with governments and leaders in the health care industry in the fight against viral pandemic and other health care crises. To learn more, visit www.nexeramed.com.
About Foss Manufacturing:
Fosshield® fabric is manufactured by Foss Manufacturing, LLC (Foss) based in Hampton, New Hampshire. Foss is a well-known leader and pioneer in the use of non-woven fabrics and specialty synthetic fibers in an ever-expanding number of environments and applications. Using new technologies and state-of-the-art computerized production, it is unrivaled in its ability to efficiently and effectively design, manufacture, convert, package, and distribute a vast array of specialty textile products worldwide. Foss is one of the world’s largest needle-punch based manufacturers, and it has the expertise and experience to support customers’ needs across virtually all applications and markets. To learn more, visit www.fossmfg.com.
Ph: +1 (954)-495-2020